• Aucun résultat trouvé

CLINICAL PRACTICE: E-cigarettes: Guiding patients in a time of uncertainty

N/A
N/A
Protected

Academic year: 2022

Partager "CLINICAL PRACTICE: E-cigarettes: Guiding patients in a time of uncertainty"

Copied!
3
0
0

Texte intégral

(1)

83

Canadian OnCOlOgy nursing JOurnal • VOlume 26, issue 1, Winter 2016 reVue Canadienne de sOins infirmiers en OnCOlOgie

FEA TUR ES /R U bR iq UE S

cliNicAl PrActice

E-cigarettes: Guiding patients in a time of uncertainty

by Arlene Court

ABSTRACT

With the emerging popularity of elec- tronic cigarettes, oncology nurses need to be well informed in order to guide patients in making choices that support a healthy lifestyle. Essential information is provided in this article through a review of conven- tional and electronic cigarette use and current recommendations. Concerns asso- ciated with electronic cigarettes are dis- cussed including nicotine addiction, lack of regulation, and lack of evidence as a smok- ing cessation aid. The potential for harm reduction is also highlighted. Suggestions are provided for how patients with cancer can be guided regarding e-cigarette use.

Key words: electronic cigarettes, oncology, nursing, smoking cessation

I

t is essential for oncology nurses to have knowledge about new trends that may impact the health of patients diagnosed with cancer. Increased inter- est and use of electronic cigarettes (e-cigarettes), as an alternative to con- ventional cigarettes illustrates such a trend (Zhu et al., 2014). An understand- ing of the history, design, and opera- tion of e-cigarettes, their current use in Canada, as well as the issues surround- ing them will facilitate oncology nurses’

ability to provide informed guidance to patients.

e-ciGArettes

The patent for e-cigarettes was issued in 2004 (Franck et al., 2014).

E-cigarettes are one type of electronic nicotine delivery systems (ENDS) that heats a solution creating an aero- sol, which is then inhaled by the user

(WHO Framework Convention on Tobacco Control, 2014). The ingre- dients of the liquid can vary between manufacturers, but is mainly composed of propylene glycol and agents that add flavour (WHO Framework Convention on Tobacco Control, 2014). E-cigarettes may or may not contain nicotine.

When present, the amount of nicotine absorbed is impacted by factors such as inhalation depth and how often the product is used (WHO Framework Convention on Tobacco Control, 2014).

E-cigarettes are made to feel and look similar to conventional cigarettes.

sMOKiNG cessAtiON AND tHe rOle OF tHe ONcOlOGY Nurse

The Canadian smoking rate is at its lowest at 15%, with 11% identifying they are daily smokers and 4% are occasional smokers (Statistics Canada, 2012). The highest incidence of smoking is found within the age groups 18–19 and 20–24 with both at 18%. Despite smoking rates being at their lowest, the impact of smoking on health is still present.

Oncology nurses are responsible for engaging with patients and families to ensure awareness of the significance of a healthy lifestyle and factors that may impact their health and treatment out- comes (Canadian Association of Nurses in Oncology, 2006). The International Society of Nurses in Cancer Care (ISNCC) (2014) specifically suggests the nurse is to assess tobacco use and ensure treatment for dependence.

Additionally, smoking cessation should be endorsed given that smoking can increase the side effects of cancer treat- ment and the risk for development of a second malignancy (ISNCC, 2014).

With an emphasis on replicating con- ventional cigarettes and the potential to contain nicotine, oncology nurses must be aware of current regulations and the use of e-cigarettes in Canada.

curreNt e-ciGArette recOMMeNDAtiONs

In 2009, Health Canada provided this recommendation, “Health Canada is advising Canadians not to purchase or use electronic smoking products, as these products may pose health risks and have not been fully evaluated for safety, quality and efficacy by Health Canada” (Healthy Canadians, 2009, para. 1). The recommendation iden- tifies that electronic smoking devices are not authorized to be sold in Canada and other approved smoking cessa- tion aids are available. More recently, the Government of Canada’s Minister of Health requested the House of Commons Standing Committee on Health to “study their potential risks and benefits, seek advice from a vari- ety of health stakeholders, and provide a report” (Parliament of Canada, 2015, p. 1). The final report, released in March 2015 with 14 recommendations, has been tabled and is now before govern- ment for response.

e-ciGArette use AMONGst cANADiANs

Though not authorized here in Canada, the Canadian Tobacco, Alcohol and Drug Survey (CTADS) (Government of Canada, 2013) reported that 9% of Canadians 15 years and older have tried an e-cigarette.

This percentage increased to 20%

amongst youth aged 15–19 and young adults aged 20–24. Of those who have tried an e-cigarette, 51% said it did not contain nicotine, 26% said it did, and 19% were unsure. Access to these products is made easy through inter- net purchases. The growth of e-cig- arettes is reflected in the number of brands for sale on the internet, which increased from 288 in 2012 to 460 in 2014 (Zhu et al., 2014).

With a focus on smoking and smok- ing cessation, insight into e-cigarette

ABOut tHe AutHOr

Arlene Court, RN, BScN, CON(C), Interprofessional Clinical Documentation Team, Clinical Educator - Nursing, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Phone: 416-480-5942

(2)

84 Volume 26, Issue 1, WInter 2016 • CanadIan onCology nursIng Journal reVue CanadIenne de soIns InfIrmIers en onCologIe

FEA TUR ES /R U bR iq UE S

use and the relationship to smoking status is necessary. Czoli, Hammond, and White (2014) explored the prev- alence of e-cigarettes use among Canadian youth and young adults (ages 16–30). From a total of 16.1% e-ciga- rette users, 5.2% were non-smokers, 18.9% former smokers, and 34.5%

were current smokers. In a four-coun- try survey, which included Canada, the International Tobacco Control asked current ENDS users why they used e-cigarettes. The majority identified to reduce harm and to help quit tradi- tional cigarettes (Adkison et al., 2013).

The Canadian perspective is also pro- vided by the CTADS as 51% of e-ciga- rettes “ever users” (current and former smokers) used it as a smoking cessation aid (Government of Canada, 2013). The prevalence of e-cigarette use in Canada compels oncology nurses to be aware of the concerns and controversies sur- rounding their use.

cONcerNs AssOciAteD WitH e-ciGArettes

There are specific concerns regard- ing e-cigarettes as seen through dis- cussions within policy statements by health organizations and governmental recommendations. An overarching con- cern, as highlighted by the American Heart Association (AHA), is the possi- bility that e-cigarettes will “renormal- ize” smoking (Bhatnagar et al., 2014).

Other aspects of e-cigarettes that are expressed as concerning include: pres- ence of nicotine, lack of regulation, and lack of evidence for support as a smok- ing cessation aid.

Availability of a nicotine product

A significant issue is the potential nicotine presence within e-cigarettes.

The AHA acknowledges the possibil- ity of nicotine addiction through the advisement that e-cigarettes should be monitored, as they can initiate or main- tain an addiction or be an opportunity for ex-smokers to start smoking again (Bhatnagar, 2014).

Youth access to nicotine. The Canadian Paediatric Society (CPS) (2015) position statement suggests that e-cigarettes may not produce the same type of smoke, but “they are essentially

nicotine delivery devices” (p. 2). The CPS proposes that e-cigarettes may lead to nicotine addiction amongst youth due to easy access and therefore rec- ommends that the same age restric- tions apply to e-cigarettes as they do for tobacco products.

Lack of regulation

Another issue, as suggested by the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO), is the lack of regulation resulting in unknown contents and, therefore, a lack of true understanding about the health implication of e-cigarettes (Brandon et al., 2015). It is interesting to note the earlier statement from the CTAS survey where 19% of e-cigarettes users did not know if it contained nicotine.

Proposed changes. The necessity of regulation is made evident by the recommendations from the House of Commons Standing Committee of Health, which proposes: (1) regulation of e-cigarettes, (2) research regarding the health effects of e-cigarettes, and (3) a requirement for manufacturers to identify ingredients (Parliament of Canada, 2015).

Insufficient evidence as a smoking cessation aid

In regards to the use of e-cigarettes as a smoking cessation aid, health organizations assert insufficient evi- dence to support their use (Brandon et al. 2015; Bhatnagar et al., 2014). There have been significant product changes and it is proposed that previous stud- ies cannot be used as evidence since e-cigarettes used within those stud- ies are now outdated (Brandon et al.

2015). ACCR/ASCO position state- ment suggests there is insufficient evi- dence to recommend ENDS to patients diagnosed with cancer due to the lack of research regarding their safety for patients undergoing surgery, chemo- therapy, or radiotherapy (Brandon et al., 2015).

POteNtiAl FOr HArM reDuctiON

There is acknowledgment of the potential harm reduction offered by

e-cigarettes. The AHA suggests the popularity of e-cigarettes when com- pared to other nicotine replacement therapy products provides “an oppor- tunity for harm reduction if smokers use them as substitutes for cigarettes”

(Bhatnagar et al., 2014, p. 1425). The ACCR/ASCO policy statement also highlights the need to prevent health consequences from e-cigarettes espe- cially in youth, but also acknowledge the potential harm reduction they may provide (Brandon et al., 2015).

Even in the presence of potential harm reduction, the lack of evidence and regulation and risk for nicotine addiction clearly indicate a cautionary approach should be taken with e-ciga- rettes. This presents oncology nurses with a challenge when making recom- mendations to patients.

tiPs FOr HOW tO GuiDe PAtieNts

The International Association for the Study of Lung Cancer, as well as the AACR/ASCO policy statements provide guidance when addressing e-cigarettes with patients. Of essence is the initial advice to patients to stop smoking given the existing and clear knowledge about the impact of conventional cigarette smoking on treatment outcomes and overall health (Cummings et al., 2014).

Weaver et al. (2014) provide an essential component for this initial step, which is to ask about all types of tobacco prod- ucts, including e-cigarettes, as patients may not realize they are considered a tobacco product.

It is necessary for patients to be supported with their quit attempts (Cummings et al., 2014). Oncology nurses must ensure patients are aware of supports available and pro- vide referrals to appropriate treatment programs. Patients should also be informed regarding the lack of evidence for e-cigarettes including the possible risks (Brandon et al., 2015). Finally, if a patient is using or considering using an e-cigarette to aid in their cessa- tion efforts, they should continually be offered evidence-based smoking ces- sation aids and followed for effects of e-cigarette use (Cummings et al., 2014).

(3)

85

Canadian OnCOlOgy nursing JOurnal • VOlume 26, issue 1, Winter 2016 reVue Canadienne de sOins infirmiers en OnCOlOgie

FEA TUR ES /R U bR iq UE S

cONclusiON

Oncology nurses have a role in pro- moting healthy living. In doing so, there is a need to address tobacco use. It is essential for oncology nurses to engage

with patients—to understand their smok- ing status and the potential or actual use of e-cigarettes—to ensure appropriate guidance, education, and recommen- dations are provided. Due to the rapidly

changing environment surrounding e-cigarettes, it is necessary to be aware of new information and regulations to enable an evidence-based approach to smoking and smoking cessation.

reFereNces

Adkison, S.E., O’Connor, R.J., Bansal- Travers, M., Hyland, A., Borland, R., Yong, H., … Fong, G.T. (2013). American Journal of Preventive Medicine, 44(3), 207–

215. doi:10.1016/j.amepre.2012.10.018 Bhatnagar, A., Whitsel, L.P., Ribisl, K.M.,

Bullen, C., Chaloupka, F., Piano, M.R.,

… Benowitz, N.; On behalf of the American Heart Association Advocacy Coordinating Committee, Council on Cardiovascular and Stroke Nursing Council, Council on Clinical Cardiology, and Council on Quality of Care and Outcomes Research. (2014). Electronic cigarettes: A policy statement from the American Heart Association. Circulation, 130(16), 1418–1436. doi:10.1161/

CIR.0000000000000107

Brandon, T.H., Goniewicz, M.L., Hanna, N.H., Hatsukami, D.K., Herbst, R.S., Hobin, J.A., … Warren, G.W. (2015).

Electronic nicotine delivery systems:

A policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology.

Journal of Clinical Oncology, 33(8), 952–

963. doi:10.1200/JCO.2014.59.4465 Canadian Association of Nurses in

Oncology. (2006). Practice Standards and Competencies for the Specialized Oncology Nurse. Retrieved from http://www.cano-acio.ca/~ASSETS/

D O C U M E N T/ P r a c t i c e / C O N E P _ S t a n d a r d s 2 0 0 6 S e p t e m b e r 2 8 _ REVISEDFor_20Website.pdf

Canadian Paediatric Society. (2014) Position Statement. E-cigarettes: Are we normalizing

public smoking? Reversing five decades of tobacco control and revitalizing nicotine dependency in children and youth in Canada. Retrieved from http://www.cps.

ca/en/documents/position/e-cigarettes Cummings, K.M., Dresler, C. M., Field,

J.K., Fox, J., Gritz, E.R., Hanna, N.H.,

… Zhou, C. (2014). E-Cigarettes and cancer patients. Journal of Thoracic Oncology, 9(4), 438–441. doi:10.1097/

JTO.0000000000000129

Czoli, C., Hammond, D., White, C.M.

(2014). Electronic cigarettes in Canada:

Prevalence of use and perceptions among youth and young adults. Canadian Journal of Public Health, 105(2), e97–e102.

Retrieved from http://journal.cpha.ca/

index.php/cjph/article/view/4119 Franck, C., Budlovsky, T., Windle, S.B.,

Filion, K.B., & Eisenberg, M.J. (2014).

Electronic cigarettes in North America.

History, use, and implications for smoking cessation. Circulation, 129(19), 1945–1952. doi:10.1161/

CIRCULATIONAHA.113.006416 Government of Canada. (2013). Canadian

Tobacco, Alcohol and Drugs Survey.

Summary of Results for 2013. Retrieved from http://healthycanadians.gc.ca/

science-research-sciences-recherches/

data-donnees/ctads-ectad/index-eng.php Healthy Canadians. (2009). Health Canada

Advises Canadians Not to Use Electronic Cigarettes. Retrieved from http://www.

healthycanadians.gc.ca/recall-alert-rappel- avis/hc-sc/2009/13373a-eng.php?_ga=1.13 8562997.760347154.1432397175

International Society of Nurses in Cancer Care. (2014). ISNCC Tobacco Position Statement. Retrieved from http://storage.

go ogleapis.com/isncc_resources/

Tobacco%20Position%20Statement%20 Final%20July%202014%20Final%20 Approved.pdf

Parliament of Canada. (2015). Vaping:

Toward a Regulatory Framework for E-cigarettes. Retrieved from http://

www.parl.gc.ca/HousePublications/

Publication.aspx?DocId=7862816&

Language=E&Mode=1&Parl=41&Ses=2 Statistics Canada. (2012). Health at a Glance.

Current Smoking Trends. Retrieved from http://www.statcan.gc.ca/pub/82- 624-x/2012001/article/11676-eng.htm Weaver, M., Breland, A., Spindle, T.,

& Eissenberg, T. (2014). Electronic cigarettes: A review of safety and clinical issues. Journal of Addiction Medicine, 8(4), 234–240. doi:10.1097/

ADM.0000000000000043

WHO Framework Convention on Tobacco Control. (2014). Electronic nicotine delivery systems. Report by WHO. Retrieved from http://apps.who.int/gb/fctc/PDF/cop6/

FCTC_COP6_10Rev1-en.pdf

Zhu, S., Sun, J.Y., Bonnevie, E., Cummins, S.E., Gamst, A., Yin, L., & Lee, M.

(2014). Four hundred and sixty brands of e-cigarettes and counting: Implications for product regulation. Tobacco Control, 23(Suppl. 3), iii3–iii9). doi:10.1136/

tobaccocontrol-2014-051670

Références

Documents relatifs

Les chercheurs ont estimé que les patients avec un cancer en cours de traitement avaient un risque de décès 1 à 2 fois plus élevé après un diagnostic de Covid-19 que les

Unit´e de recherche INRIA Rennes, Irisa, Campus universitaire de Beaulieu, 35042 RENNES Cedex Unit´e de recherche INRIA Rh ˆone-Alpes, 655, avenue de l’Europe, 38330 MONTBONNOT

Compared with finite mixture of linear regression mod- els, the newly proposed models relax the linearity assumption on the regression functions, and allow the regression function

This is in contrast with previous articles that considers multiple test- ing under special dependence structures; for example, Sun and Cai (2009) developed a multiple testing

i=1 I i be the number of relevant entities defined by I.. In BARD, we use λ = 1 as the default setting, and allow the user to specify the value of λ based on their own judgment for

The two-stage approach consists of (a) reducing the ultrahigh dimensionality by using the proposed procedure and (b) applying regularization methods for dimension-reduced

The domain to capture the nursing specialty in a clinical research setting was titled “clinical research nursing.” Five theoretical dimensions had been identified previously:

Perceptions of health professionals about inappropriate or low-value practices and about recommendations for improving the appropriateness of clinical practice in the hospital